Lion Biotechnologies’ has posted long-term follow-up data for its Phase II trial for metastatic melanoma, conducted by the National Cancer Institute (NCI) and utilizing the tumor-infiltrating lymphocyte (TIL) technology currently licensed by the company and being developed under a Cooperative Research and Development Agreement (CRADA) with the NCI. The single-site trial included 93 patients in three cohorts. The follow-up data reported by the NCI show an Objective Response (OR) rate of 49...